United Therapeutics Corp (UTHR) - Financial and Strategic SWOT Analysis Review

United Therapeutics Corp (UTHR) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

United Therapeutics Corp (United Therapeutics) develops and commercializes products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's product portfolio includes prostacyclin analogs including Remodulin (treprostinil) injection; Tyvaso (treprostinil) inhalation solution; and Orenitram (treprostinil). Adcirca (tadalafil) is a phosphodiesterase type 5 (PDE-5) inhibitor and Unituxin (dinutuximab), a monoclonal antibody for oncologic applications, are the other products. Its product candidates include monoclonal antibodies (mAbs), glycobiology antiviral agents, and cell-based therapies. The company also develops engineered lungs for transplantation in the pre-clinical stage. It manufactures products in its facility in Silver Spring, Maryland. It markets its products in the US, Europe, South America, and Israel. United Therapeutics is headquartered in Silver Spring, Maryland, the US.

United Therapeutics Corp Key Recent Developments

May 01,2024: United Therapeutics Reports First Quarter 2024 Financial Results
Apr 16,2024: United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
Mar 05,2024: United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
Dec 29,2023: United Therapeutics Corp. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
United Therapeutics Corp - Key Facts
United Therapeutics Corp - Key Employees
United Therapeutics Corp - Key Employee Biographies
United Therapeutics Corp - Major Products and Services
United Therapeutics Corp - History
United Therapeutics Corp - Company Statement
United Therapeutics Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
United Therapeutics Corp - Business Description
Product Category: Adcirca
Overview
Performance
Product Category: Orenitram
Overview
Performance
Product Category: Other
Performance
Product Category: Remodulin
Overview
Performance
Product Category: Tyvaso
Overview
Performance
Product Category: Unituxin
Overview
Performance
Geographical Segment: Rest-of-World
Performance
Geographical Segment: United States
Performance
R&D Overview
United Therapeutics Corp - Corporate Strategy
United Therapeutics Corp - SWOT Analysis
SWOT Analysis - Overview
United Therapeutics Corp - Strengths
United Therapeutics Corp - Weaknesses
United Therapeutics Corp - Opportunities
United Therapeutics Corp - Threats
United Therapeutics Corp - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
United Therapeutics Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 01, 2024: United Therapeutics Reports First Quarter 2024 Financial Results
Apr 16, 2024: United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
Mar 05, 2024: United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
Dec 29, 2023: United Therapeutics Corp. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nov 01, 2023: United Therapeutics Reports Third Quarter 2023 Financial Results
Aug 02, 2023: United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
May 03, 2023: United Therapeutics Corporation Reports First Quarter 2023 Financial Results
Apr 18, 2023: United Therapeutics to Feature Clinical Data across Its Commercial and Development Portfolio at Upcoming Scientific Meetings
Feb 22, 2023: United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
United Therapeutics Corp, Key Facts
United Therapeutics Corp, Key Employees
United Therapeutics Corp, Key Employee Biographies
United Therapeutics Corp, Major Products and Services
United Therapeutics Corp, History
United Therapeutics Corp, Subsidiaries
United Therapeutics Corp, Key Competitors
United Therapeutics Corp, Ratios based on current share price
United Therapeutics Corp, Annual Ratios
United Therapeutics Corp, Annual Ratios (Cont...1)
United Therapeutics Corp, Annual Ratios (Cont...2)
United Therapeutics Corp, Interim Ratios
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
United Therapeutics Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
United Therapeutics Corp, Performance Chart (2019 - 2023)
United Therapeutics Corp, Ratio Charts
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
United Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings